AbCellera Investor Conference Presentation Deck

CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 13 PRE-PARTNERED PROGRAMS: PANDEMIC RESPONSE FIRST PRE-PARTNERED PROGRAM IN COVID-19 RESULTED IN TREATMENTS FOR ~2.5M PATIENTS Together with our partner, Lilly, AbCellera co-developed two antibody treatments authorized by the US FDA to treat COVID-19. bamlanivimab Nov 2020 - US FDA Authorization bebtelovimab Feb 2022- US FDA Authorization new candidate Today - 3rd therapeutic antibody for COVID-19 in preclinical development

View entire presentation